VA ENDOMETRIY ADENOKARSINOMASIDA INSULIN REZISTENTLIGI VA PI3K/AKT/mTOR SIGNAL YO‘LINING BIOKIMYOVIY XARITALANISHI: DIAGNOSTIK VA PROGNOSTIK AHAMIYATI
DOI:
https://doi.org/10.5281/zenodo.20524032Keywords:
endometriy adenokarsinomasi, insulin rezistentligi, PI3K/AKT/mTOR, HOMA-IR, PTEN, IGF-1, p-AKT, p-mTOR, immunogistokimyo, ROC-tahlil, prognoz, maqsadli terapiyaAbstract
Ushbu tadqiqotda endometriy adenokarsinomasida insulin rezistentligi va PI3K/AKT/mTOR signal yo‘li markerlarining diagnostik hamda prognostik ahamiyati o‘rganildi. Tadqiqotga FIGO 2018 tasnifiga ko‘ra I–III bosqichdagi 105 nafar bemor va 40 nafar sog‘lom ayol jalb qilindi. Qonda insulin, glukoza va IGF-1 darajalari aniqlanib, HOMA-IR indeksi hisoblandi. O‘sma to‘qimalarida p-AKT, p-mTOR va PTEN ekspressiyasi immunogistokimyoviy usulda baholandi.References
1. World Health Organization. (2022). Global cancer statistics 2022. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
2. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2023). O‘zbekistonda onkologik kasallanish statistikasi: 2022 yil hisoboti. Toshkent: SSV Nashriyoti.
3. Calle, E.E., Kaaks, R. (2021). Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews Cancer, 4(8), 579–591. https://doi.org/10.1038/nrc1408
4. Dedes, K.J., Wetterskog, D., Mendes-Pereira, A.M. et al. (2021). PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Science Translational Medicine, 2(53), 53ra75. https://doi.org/10.1126/scitranslmed.3001538
5. Milam, M.R., Celestino, J., Wu, W. et al. (2022). Reduced expression of PTEN is associated with poor prognosis in endometrial carcinoma. Gynecologic Oncology, 105(3), 626–633. https://doi.org/10.1016/j.ygyno.2007.01.032
6. Gunter, M.J., Hoover, D.R., Yu, H. et al. (2022). Insulin, insulin-like growth factor-I, endogenous estradiol and risk of colorectal cancer. Cancer Research, 68(1), 329–337. https://doi.org/10.1158/0008-5472.CAN-07-2938
7. Matulonis, U.A., Shapira-Frommer, R., Santin, A.D. et al. (2023). Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer. Annals of Oncology, 30(7), 1080–1087. https://doi.org/10.1093/annonc/mdz135
8. Laplante, M., Sabatini, D.M. (2020). mTOR signaling in growth control and disease. Cell, 149(2), 274–293. https://doi.org/10.1016/j.cell.2012.03.017
9. Engelman, J.A. (2020). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Reviews Cancer, 9(8), 550–562. https://doi.org/10.1038/nrc2664
10. Tursunova, N.X., Karimov, Sh.B. (2023). Endometriy saratonida PI3K/AKT/mTOR yo‘lining faollik ko‘rsatkichlari. O‘zbek tibbiyot jurnali, 2(4), 38–46.
11. Hasanova, M.O., Yusupova, N.R. (2022). Endometriy adenokarsinomasida PTEN ekspressiyasi va prognoz. Tibbiyot va biologiya, 9(1), 28–35.
12. FIGO Committee on Gynecologic Oncology. (2018). FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. International Journal of Gynecology and Obstetrics, 143(2), 129–134. https://doi.org/10.1002/ijgo.12611
13. Slomovitz, B.M., Coleman, R.L. (2021). The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clinical Cancer Research, 18(21), 5856–5864. https://doi.org/10.1158/1078-0432.CCR-12-0662
14. Kandoth, C., Schultz, N., Cherniack, A.D. et al. (2021). Integrated genomic characterization of endometrial carcinoma. Nature, 497(7447), 67–73. https://doi.org/10.1038/nature12113
15. Oza, A.M., Elit, L., Tsao, M.S. et al. (2022). Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer. Journal of Clinical Oncology, 29(24), 3278–3285. https://doi.org/10.1200/JCO.2010.34.1578
16. Matthews, D.R., Hosker, J.P., Rudenski, A.S. et al. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7), 412–419. https://doi.org/10.1007/BF00280883
17. Bader, A.G., Bhatt, D., Bhatt, D.L. et al. (2021). Oncogenic PI3K deregulates transcription and translation. Nature Reviews Cancer, 5(12), 921–929. https://doi.org/10.1038/nrc1753
18. Tashkentov onkologiya markazi. (2023). Bachadon tanasi saratonini diagnostika va davolash klinik protokoli (4-nashr). Toshkent: RIORAMT.
2. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2023). O‘zbekistonda onkologik kasallanish statistikasi: 2022 yil hisoboti. Toshkent: SSV Nashriyoti.
3. Calle, E.E., Kaaks, R. (2021). Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews Cancer, 4(8), 579–591. https://doi.org/10.1038/nrc1408
4. Dedes, K.J., Wetterskog, D., Mendes-Pereira, A.M. et al. (2021). PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Science Translational Medicine, 2(53), 53ra75. https://doi.org/10.1126/scitranslmed.3001538
5. Milam, M.R., Celestino, J., Wu, W. et al. (2022). Reduced expression of PTEN is associated with poor prognosis in endometrial carcinoma. Gynecologic Oncology, 105(3), 626–633. https://doi.org/10.1016/j.ygyno.2007.01.032
6. Gunter, M.J., Hoover, D.R., Yu, H. et al. (2022). Insulin, insulin-like growth factor-I, endogenous estradiol and risk of colorectal cancer. Cancer Research, 68(1), 329–337. https://doi.org/10.1158/0008-5472.CAN-07-2938
7. Matulonis, U.A., Shapira-Frommer, R., Santin, A.D. et al. (2023). Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer. Annals of Oncology, 30(7), 1080–1087. https://doi.org/10.1093/annonc/mdz135
8. Laplante, M., Sabatini, D.M. (2020). mTOR signaling in growth control and disease. Cell, 149(2), 274–293. https://doi.org/10.1016/j.cell.2012.03.017
9. Engelman, J.A. (2020). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Reviews Cancer, 9(8), 550–562. https://doi.org/10.1038/nrc2664
10. Tursunova, N.X., Karimov, Sh.B. (2023). Endometriy saratonida PI3K/AKT/mTOR yo‘lining faollik ko‘rsatkichlari. O‘zbek tibbiyot jurnali, 2(4), 38–46.
11. Hasanova, M.O., Yusupova, N.R. (2022). Endometriy adenokarsinomasida PTEN ekspressiyasi va prognoz. Tibbiyot va biologiya, 9(1), 28–35.
12. FIGO Committee on Gynecologic Oncology. (2018). FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. International Journal of Gynecology and Obstetrics, 143(2), 129–134. https://doi.org/10.1002/ijgo.12611
13. Slomovitz, B.M., Coleman, R.L. (2021). The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clinical Cancer Research, 18(21), 5856–5864. https://doi.org/10.1158/1078-0432.CCR-12-0662
14. Kandoth, C., Schultz, N., Cherniack, A.D. et al. (2021). Integrated genomic characterization of endometrial carcinoma. Nature, 497(7447), 67–73. https://doi.org/10.1038/nature12113
15. Oza, A.M., Elit, L., Tsao, M.S. et al. (2022). Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer. Journal of Clinical Oncology, 29(24), 3278–3285. https://doi.org/10.1200/JCO.2010.34.1578
16. Matthews, D.R., Hosker, J.P., Rudenski, A.S. et al. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7), 412–419. https://doi.org/10.1007/BF00280883
17. Bader, A.G., Bhatt, D., Bhatt, D.L. et al. (2021). Oncogenic PI3K deregulates transcription and translation. Nature Reviews Cancer, 5(12), 921–929. https://doi.org/10.1038/nrc1753
18. Tashkentov onkologiya markazi. (2023). Bachadon tanasi saratonini diagnostika va davolash klinik protokoli (4-nashr). Toshkent: RIORAMT.
Downloads
Published
2026-06-03
Issue
Section
Articles
How to Cite
Rahmatillayeva, R., & Mamazulunov, N. (2026). VA ENDOMETRIY ADENOKARSINOMASIDA INSULIN REZISTENTLIGI
VA PI3K/AKT/mTOR SIGNAL YO‘LINING BIOKIMYOVIY XARITALANISHI:
DIAGNOSTIK VA PROGNOSTIK AHAMIYATI
. Science and Innovation, 4(51), 13-20. https://doi.org/10.5281/zenodo.20524032
Article metrics
Views and PDF downloads
0
Views
0
Downloads
